Implementation of the malaria candidate vaccine RTS,S/AS01
As vaccine manufacturers tackle increasingly intractable pathogens, vaccines will be developed that show effi cacy, but that are less effi cacious than established vaccines. Consequently, regulatory and public health authorities will be faced with diffi cult decisions about whether such vaccines should be recommended for implementation and, if so, under what circumstances. The RTS,S/AS01 malaria candidate vaccine provides an important example of such a challenge.
After a long period of development, 1,2 a large phase 3 trial 3 of RTS,S/AS01 in children aged 5-17 months at fi rst vaccination showed a vaccine effi cacy of 28·3% (95% CI 23·3-32·9%) against clinical malaria in children who received three doses, and of 36·3% (31·8-40·5%) in those given a fourth dose, during 48 months of follow-up. The vaccine also provided signifi cant protection against severe malaria and hospital admissions in the group of children who received a fourth dose. 3 An average of 1774 cases (95% CI 1387-2186) of clinical malaria were averted per 1000 children vaccinated in the four-dose group. An unexplained increase in incidence of meningitis was identifi ed as a safety signal. Effi cacy was lower in infants who received their fi rst dose of vaccine aged 6-12 weeks than in children aged 5-17 months. Could this vaccine with restricted effi cacy still have a useful role in malaria control? In The Lancet, Melissa Penny and colleagues 4 provide some important new information that suggests that it could.
Four modelling groups have worked together to estimate the potential impact of RTS,S/AS01 on malaria cases and deaths. Overall, the models gave similar results. On the basis of assumptions of 72% coverage with a four-dose schedule, a 15 year follow-up period (needed to account for any age shift in malaria incidence), and a vaccine price of US$2-10 per dose, the models predicted that in the areas where the parasite prevalence in children aged 2-10 years (PfPR 2-10 ; a widely used measure of the intensity of malaria transmission) lies between 10% and 65%, RTS,S/AS01 would prevent 116 480 (range 31 450-160 410) cases of clinical malaria and 484 (190-860) deaths per 100 000 fully vaccinated children. At $5 a dose, the cost per disability-adjusted life-year (DALY) averted in areas with a PfPR 2-10 of 10% or more would be less than $100, an amount comparable to that of other malaria control measures. 3 As recognised by the investigators, the study includes several unproven assumptions. The most important of these is the assumption that RTS,S/AS01 will have a signifi cant impact on mortality, a key factor for decision makers and for calculation of DALYs; this assumption is not yet supported by empirical data. However, the quality of care provided to children in trials of RTS,S/AS01 was exemplary and, in the phase 3 trial, mortality was very low in all study groups. 5 Trials of seasonal malaria chemoprevention also failed to show a statistically signifi cant impact on mortality, 6 but this intervention is having a major impact when deployed on a large scale. By contrast, trials of insecticide-treated nets did show an impact on mortality, 7 but these studies were done at the community level, with less intensive follow-up of individual participants. The assumption that RTS,S/AS01 will have a signifi cant impact on mortality if deployed in high transmission areas is a reasonable one.
The European Medicines Agency reviewed the effi cacy and safety of RTS,S/AS01 and, under article 58, gave a positive opinion on its use in both the younger and older age groups included in the phase 3 trial. 8 By contrast, WHO's Strategic Advisory Group of Experts on Immunization and Malaria Policy Advisory Committee only recommended use of the vaccine in children in the older age group. 9 They also recommended that several pilot studies should be undertaken before widespread deployment of the vaccine. The objective of these pilot projects would be to assess whether routine immunisation programmes can deliver the four-dose schedule eff ectively, whether the vaccine prevents deaths, and whether the safety signals detected in the phase 3 trial were just chance fi ndings. To abandon RTS,S/AS01 at this point would be a major setback in the endeavour to develop a malaria vaccine, in addition to vaccines against other infections present mainly in low-income countries, and a discouragement to major pharmaceutical companies and public-private partnerships to engage in these activities. Therefore, these pilot programmes must move forward quickly, should be large enough to evaluate The migration crisis is one of the most pressing global challenges, as worldwide displacement is now at the highest level ever recorded. Latest global estimates by the UN Commissioner for Refugees (UNHCR) show that 59·5 million people are forcibly displaced as a result of persecution, confl ict, generalised violence, or human rights violations. 1 The estimated refugee population reached an unprecedented 19·6 million individuals worldwide in 2015-half of them being children-and the number is steadily increasing, with Syria as the leading country of origin of refugees.
1,2 A lengthy drought preceded the Syrian crisis that led to a large movement of people into cities and contributed to instability; recent evidence suggests that risks of such droughts in the region are more than doubled as a result of climate change. 3 More than a million refugees and migrants arrived in the European Union in 2015. 4 The growing infl ux of vulnerable populations poses many challenges to host countries, not least with regard to preparedness and resilience of health systems and access to health-care services. Furthermore, increasing numbers of refugees are likely in future as a result of a complex combination of driving forces, such as faltering and unequal economic growth, population increases, confl icts, and environmental change. The need to develop more eff ective approaches that respond to the health needs of displaced populations and address the root causes of displacement is therefore imperative.
A refugee is someone who "owing to a well-founded fear of being persecuted for reasons of race, religion, nationality, membership of a particular social group or political opinion, is outside the country of his nationality, and is unable to, or owing to such fear, is unwilling to avail himself of the protection of that country". 5 Refugees experience conditions of vulnerability, marginalisation, and poverty, in addition to the high stress of displacement, which seriously aff ect the health of these populations, including women, children, and older people.
Evidence suggests that refugees often have acute mental health problems and trauma symptoms, notably depression and post-traumatic stress disorder (PTSD), related to organised violence, torture, human Refugees: towards better access to health-care services an impact on mortality, and will need to be followed up as soon as possible with more widespread deployment of the vaccine in appropriate epidemiological situations if they show that the vaccine can be delivered, is eff ective, and is safe. RTS,S/AS01 should not be regarded as a replacement for other control measures, but rather as an additional method to be used in areas where malaria is proving diffi cult to control despite high levels of coverage with established control measures, and possibly in other specifi c circumstances, such as elimination programmes and control of malaria in areas where transmission is very seasonal. 
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